(一)Core objectives of the FDA reformInternational harmonization: Align the U.S. medical device regulatory system with major global regulators to reduce duplicate compliance costs for enterprises;
Improve efficiency: Drive consistent device regulation based on internationally recognized consensus standards;
Accelerate market access: Bring safe, effective and high-quality medical devices to patients faster.
The FDA has assessed that ISO 13485:2016 is substantially equivalent to the legacy QS Regulation and provides an equivalent level of quality system assurance.
(二)How this QMSR reform impacts enterprisesPreviously, the US adopted its own QS Regulation (21 CFR 820), which differed from ISO 13485 used globally. Enterprises had to maintain two separate systems. With QMSR directly aligned to ISO 13485:- One single system can satisfy requirements for FDA, EU, Canada, Japan and many other markets simultaneously;
- Enterprises no longer need to maintain a separate, divergent quality system documentation package exclusively for the US market;
- At the same time, the inspection scope has expanded (management reviews and supplier audit reports are no longer exempted), and complete system records must be maintained.
(一)Full replacement of inspection methodology: QSIT retired, new CP 7382.850 activatedOfficially retired:Quality System Inspection Technique (QSIT), original inspection procedure 7382.845, and PMA-related inspection procedure 7383.001 are no longer in use;Officially activated:Revised Medical Device Manufacturer Inspection Program (7382.850), with inspection workflows fully aligned to QMSR requirements.This means FDA inspectors have adopted systematic changes in inspection logic, review priorities and deficiency classification. Enterprises cannot prepare for inspections based on legacy QSIT thinking.(二)Removal of the exempt records listThis is one of the most impactful practical changes under the reform:Legacy QS Regulation 820.180(c) exempted three categories of records from FDA inspection review: internal audit reports, supplier audit reports, and management review reports. This exemption is fully eliminated upon QMSR effective date.
The FDA clarifies that starting February 2, 2026, inspectors have the authority to review management reviews, internal quality audits and supplier audit reports.The rationale is straightforward:these documents are already provided to other regulators, so no extra burden is created; these records are required to be retained in normal business operations and shall be available upon request during inspections.
(三)Historical records are subject to review against the new standardThe FDA clarifies that inspectors may examine records created before February 2, 2026 to assess compliance with QMSR requirements.Given the substantial similarity between legacy QS requirements and QMSR, the FDA recommends enterprises proactively conduct a gap analysis to demonstrate that documents and records generated prior to QMSR effective date also satisfy QMSR requirements.(四)FDA inspection ≠ MDSAP, nor ISO 13485 certificationThe FDA clarifies several common misconceptions:- FDA inspections do not follow MDSAP audit plans or workflows;
- The FDA does not require or issue ISO 13485 certificates of conformity;
- Holding an ISO 13485 certificate does not exempt an enterprise from FDA inspections;
- FDA inspections are scheduled based on risk factors and assess compliance with FDA regulations. MDSAP is a voluntary third-party audit program conducted on a three-year annual cycle.
In short:QMSR references ISO 13485, but FDA inspections remain FDA-led activities and will not be replaced by ISO certification audits.
四、Official Responses to Frequently Asked QuestionsQ1:What happens if ISO 13485 is revised in the future?A:The FDA will evaluate the impact of standard revisions and amend QMSR through formal rulemaking procedures if necessary. QMSR will not automatically update to follow standard revisions.Q2:Where can enterprises obtain the ISO 13485 standard text?A:The read-only version is available for free viewing at the ANSI IBR Online Reading Room and ISO Online Browsing Platform.Q3:How should enterprises prepare for the revised FDA inspections?A:The FDA advises enterprises to be ready to discuss and provide records demonstrating compliance with QMSR requirements. The best preparation is to ensure products continuously meet applicable FDA requirements.
五、Recommendations for Chinese Medical Device ExportersConduct an immediate QMSR gap analysis:Compare against ISO 13485:2016 and new QMSR requirements to fully review existing quality system documents. Focus on verifying that management review records, internal audit reports and supplier audit files are complete, standardized and readily retrievable.Retrain inspection teams:Legacy QSIT frameworks are no longer applicable. Train quality, regulatory and production teams on the inspection logic of the new compliance program 7382.850, and simulate inspection scenarios in advance.Do not confuse MDSAP with FDA inspections:Even if you have passed MDSAP audits, you cannot relax preparation for FDA inspections. QMSR only aligns the referenced standard text; FDA inspection style, deficiency judgment and enforcement remain characteristic of US regulation.Sort historical records in advance:Since pre-effective-date records are subject to review under the new standard, organize system documents and audit reports generated before February 2026 as soon as possible. Remediate gaps promptly to avoid disadvantage during inspections.
Overall, the implementation of QMSR represents a major step toward international alignment for U.S. medical device regulation. In the long run, it benefits enterprises operating across multiple markets, as one single system can satisfy more regulatory requirements. In the short term, however, revised inspection practices and expanded record scope raise higher standards for system maturity and inspection readiness.or further inquiries, please contact Wiselink.